Yes, Botox Can Treat Headaches — But Only a Specific, Severe Type

The claim that Botox can treat headaches is true — but the full picture matters enormously. Botox is not a general headache remedy. It is FDA-approved specifically for the prevention of chronic migraine in adults, a condition defined as 15 or more headache days per month with headaches lasting at least four hours. The FDA granted this approval in October 2010, and the evidence behind it is among the strongest available for any headache treatment.

The clinical foundation rests on two large Phase 3 randomized controlled trials published in Cephalgia in 2010. PREEMPT 1 (N=679) found that onabotulinumtoxinA reduced mean headache days by 7.8 compared to 6.4 for placebo over 24 weeks, a statistically significant result (p=0.006). PREEMPT 2 (N=705) showed an even larger effect: 9.0 headache days reduced versus 6.7 for placebo (p<0.001). These are not marginal findings — they represent consistent, reproducible reductions in one of the most disabling headache conditions that exists.

The evidence does not stop at two trials. A 2012 Cochrane systematic review by Derry et al. independently confirmed that botulinum toxin significantly reduced headache frequency compared to placebo, finding approximately two fewer headache days per month on average. The American Headache Society, in its 2019 position statement, assigned onabotulinumtoxinA Level A evidence for chronic migraine prevention — the highest classification the society awards, reserved for treatments backed by multiple high-quality trials. The UK's National Institute for Health and Care Excellence (NICE) recommends it for adults with chronic migraine who have not responded to at least three prior preventive treatments.

The steelman version of skepticism about this claim is reasonable: Botox is famous as a cosmetic wrinkle treatment, and the idea that it prevents headaches sounds like marketing overreach. That skepticism is worth taking seriously — but it breaks down against the mechanism. Botox does not work here through muscle relaxation, as it does cosmetically. The current scientific understanding is that it inhibits peripheral nociceptive signaling, meaning it interrupts pain pathways at the nerve level. That is a distinct and plausible mechanism supported by the trial outcomes.

What is genuinely true, and worth conceding, is that the scope of the claim is frequently overstated in popular coverage. Botox has not been shown to work for episodic migraine (fewer than 15 headache days per month) or for tension-type headaches. Applying the FDA approval broadly to all headache types would be inaccurate. The PREEMPT trials enrolled only chronic migraine patients, so the evidence simply does not extend beyond that population.

The manipulation pattern to watch for here is scope inflation: taking a real, well-supported finding and quietly removing its boundaries. When someone says Botox treats headaches without specifying chronic migraine, they are technically gesturing at a true fact while implying something much broader. The question to ask every time is: which headache type, in which patients, under what conditions? In this case, the answer is specific, well-documented, and backed by Level A evidence — but only when the boundaries are kept intact.